Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - MPV Packaging Pty Ltd, Biocsl Pty Ltd, Fresenius Kabi Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, addresses the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components, to ensure they meet safety, quality, and efficacy standards. The Act was introduced to fill a critical gap in the regulation of therapeutic goods, providing a comprehensive legislative framework for the control of these products. The policy objective of the Act is to protect public health by ensuring that therapeutic goods available in Australia are of an acceptable standard and are not misrepresented. The 2014 publication by the Therapeutic Goods Administration, an agency of the Department of Health, provides an update on the licences granted to manufacturers of therapeutic goods, ensuring transparency and compliance with the legislative requirements.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, supply, or distribution of therapeutic goods in Australia. Specifically, this Act applies to companies and individuals who engage in activities related to the production and sale of therapeutic goods, which include medicines, medical devices, and other health-related products. The Act establishes the framework for licensing and regulating these activities to ensure that therapeutic goods are safe, of high quality, and effective for their intended use. The scope of the Act is national, covering all states and territories within the Commonwealth of Australia. It also extends to the regulation of imports and exports of therapeutic goods, thereby impacting entities engaged in cross-border trade. The Act includes provisions for exemptions and thresholds, particularly for small-scale manufacturers and research activities, but generally mandates licences for entities involved in the commercial manufacture of therapeutic goods. Additionally, the application and interpretation of the Act may be further detailed through subordinate instruments issued by the Therapeutic Goods Administration, which can clarify or expand on specific requirements or regulatory practices.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) is a pivotal piece of legislation governing the regulation of therapeutic goods in Australia, and Section 38 plays a crucial role by detailing the requirements for the manufacture of these goods. Under this section, the Secretary of the Department of Health, Therapeutic Goods Administration (TGA), is authorised to grant licences to entities that meet specified criteria for manufacturing therapeutic goods. This legislative framework ensures that only qualified and compliant entities can manufacture such goods, thereby protecting public health and safety. The Licence to Manufacture Therapeutic Goods is a formal authorisation granted to companies like MPV Packaging Pty Ltd, bioCSL Pty Ltd, and Fresenius Kabi Australia Pty Limited, as mentioned in the publication (s. 38). Entities granted a Licence to Manufacture Therapeutic Goods under the Act are obligated to adhere to stringent regulatory standards to maintain the licence's validity. These obligations include, but are not limited to, ensuring that the manufacturing processes meet the required quality and safety standards as stipulated by the TGA. The licensed companies must also comply with good manufacturing practices (GMP), which are designed to minimise the risk of contamination and ensure the therapeutic goods produced are safe, effective, and of high quality. Furthermore, these companies are required to keep detailed records of their manufacturing processes and submit regular reports to the TGA to demonstrate compliance with the Act. Failure to comply with the requirements of the Therapeutic Goods Act 1989, or any conditions attached to a licence granted under Section 38, can lead to serious consequences. The Act stipulates that any breach of its provisions, including the manufacturing licence conditions, can result in civil or criminal penalties. For instance, an entity that fails to comply with the quality and safety standards could face fines of up to $1,215,000 for a corporation and $243,000 for an individual, as prescribed by the Act. Additionally, ongoing non-compliance may lead to the suspension or revocation of the manufacturing licence, thereby preventing the entity from continuing to manufacture therapeutic goods. In summary, Section 38 of the Therapeutic Goods Act 1989 mandates that only entities that meet specific criteria and obtain a Licence to Manufacture Therapeutic Goods can legally produce such goods in Australia. The licensed entities are bound by strict regulatory obligations to ensure the safety and quality of the products they manufacture. Non-compliance with these obligations can result in severe civil and criminal penalties, underscoring the importance of adherence to the Act’s provisions. This regulatory framework is essential in safeguarding public health by ensuring that only high-quality therapeutic goods are available in the Australian market.